Anti-NFKB1 Polyclonal Antibody is a Rabbit antibody targeting NFKB1. Anti-NFKB1 Polyclonal Antibody can be used in WB,IHC-P,IHC-Fr,IF.

IgG

Human,Mouse,Rat (predicted:Chicken,Dog,Pig,Cow)

1. Sample: Lung (Mouse) lysate at 30 μg;
Primary: Anti-NFkB p105/p50 (TMAB-01233) at 1:300 dilution;
Secondary: HRP conjugated Goat-Anti-rabbit Igg (secondary antibody) at 1: 5000 dilution;
Predicted band size: 48/105 kDa
Observed band size: 110 kDa
2. Sample: Brain (Mouse) lysate at 30 μg;
Primary: Anti-NFkB p105/p50 (TMAB-01233) at 1:300 dilution;
Secondary: HRP conjugated Goat-Anti-rabbit Igg (secondary antibody) at 1: 5000 dilution;
Predicted band size: 48/105 kDa
Observed band size: 50 kD
3. Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (NFkB p50) Polyclonal Antibody, Unconjugated (TMAB-01233) at 1:500 overnight at 4°C, followed by a conjugated secondary for 20 min and DAB staining.
4. Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (NFkB p105) Polyclonal Antibody, Unconjugated (TMAB-01233) at 1:200 overnight at 4°C, followed by operating according to SP Kit (Rabbit) instructionsand DAB staining.
5. Paraformaldehyde-fixed, paraffin embedded (rat bladder); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (NFkB p105) Polyclonal Antibody, Unconjugated (TMAB-01233) at 1:200 overnight at 4°C, followed by operating according to SP Kit (Rabbit) instructionsand DAB staining.
6. Paraformaldehyde-fixed, paraffin embedded (rat uterus); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (NFkB p105) Polyclonal Antibody, Unconjugated (TMAB-01233) at 1:200 overnight at 4°C, followed by operating according to SP Kit (Rabbit) instructionsand DAB staining.
7. Sample:
Lane 1: Human Raji cell lysates
Lane 2: Human MCF-7 cell lysates
Lane 3: Human Jurkat cell lysates
Primary: Anti-NFKB1 (TMAB-01233) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 48/105 kDa
Observed band size: 135 kDa

WB: 1:500-2000; IHC-P: 1:100-500; IHC-Fr: 1:100-500; IF: 1:100-500

Polyclonal

KLH conjugated synthetic peptide: human Nuclear factor NF-kappa-B p50 subunit

Human

NFKB1

Nuclear factor NF-kappa-B p105 subunit

p50,NFkB pathway,p50,NFkB pathway,Transcription Factors,Macrophage / Inflamm.,NFkB Pathway

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.